JGC
ITCI

J. Goldman & Co’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

J. Goldman & Co’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-37,500
Closed -$592K – 460
2017
Q3 		$592K Buy
+37,500
New +$550K 0.03% 265
2016
Q4 		– Sell
-25,000
Closed -$381K – 413
2016
Q3 		$381K Buy
+25,000
New +$1.01M 0.02% 273

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

J. Goldman & Co's ITCI Position: Q1 2024 in Review

J. Goldman & Co sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2024, closing a stake of 106,080 shares — an estimated $7.6M sold.

J. Goldman & Co first reported a position in ITCI in Q3 2016 and held it in 11 quarters. The position peaked at $7.6M in Q4 2023. 345 funds tracked by Wall St. Rank hold ITCI as of Q1 2024.

  • J. Goldman & Co reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2024 after selling out during the quarter.
  • J. Goldman & Co sold 106,080 Intra-Cellular Therapies Inc. shares in Q1 2024, an estimated $7.6M.
  • J. Goldman & Co first reported a position in Intra-Cellular Therapies Inc. in Q3 2016 and held it in 11 quarters.
  • J. Goldman & Co's Intra-Cellular Therapies Inc. position peaked at $7.6M in Q4 2023.
  • 345 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2024.

Based on J. Goldman & Co's 13F filing for Q1 2024, filed 15 May 2024.